跳至主要内容
临床试验/NCT07107711
NCT07107711已完成不适用

One-Stop Hybrid Versus Conventional Surgery for Acute Type A Aortic Dissection: A Randomized Controlled Trial

The First Hospital of Hebei Medical University2 个研究点 分布在 1 个国家目标入组 140 人开始时间: 2021年1月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
140
试验地点
2
主要终点
Incidence of the Composite Endpoint of 30-day Mortality, Stroke, and Acute Kidney Injury (Stage 2 or 3)

研究概览

简要总结

This is a prospective, randomized controlled trial designed to compare the clinical efficacy and short-term outcomes of one-stop hybrid surgery versus conventional total arch replacement with frozen elephant trunk (FET) in patients with acute Stanford Type A Aortic Dissection. The study evaluates differences in perioperative metrics, postoperative complications, 30-day survival, aortic remodeling, and quality of life.

详细描述

Stanford Type A Aortic Dissection (TAAD) is a life-threatening condition requiring urgent surgical repair. This study tests the hypothesis that a one-stop hybrid surgery protocol is superior to conventional repair. 140 patients with acute TAAD were randomized to one of two groups. The experimental group received a one-stop hybrid surgery, which combines open total arch replacement using a standard branched surgical graft with the antegrade deployment of a separate stent graft, performed under moderate hypothermia. The active comparator group underwent conventional total arch replacement using an integrated frozen elephant trunk (FET) hybrid prosthesis, performed under deep hypothermic circulatory arrest. The study's main objective is to compare key clinical outcomes between the two surgical strategies, including a primary composite endpoint of 30-day mortality, stroke, and acute kidney injury, to provide evidence on the optimal surgical approach for this high-risk population.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Age 18-70 years.
  • •Diagnosis of acute TAAD (symptom onset <72 hours) confirmed by imaging, with dissection involving the aortic arch requiring total arch replacement.
  • •Relative hemodynamic stability, defined as a systolic blood pressure >90 mmHg without high-dose vasopressor support (norepinephrine >0.1 µg/kg/min).
  • •Provision of informed consent.

排除标准

  • •Age >70 years.
  • •Stanford type B or non-dissection pathologies.
  • •Life-threatening comorbidities prohibitive of major cardiac surgery (e.g., advanced multiorgan failure from other causes, active malignancy).
  • •Absolute contraindications to surgery.
  • •History of previous ascending aorta or aortic arch surgery.
  • •Inability to provide informed consent.

研究组 & 干预措施

Experimental: Hybrid Group (n=70)

Experimental

Patients were randomized to undergo one-stop hybrid surgery, which included total aortic arch replacement with a standard 4-branched artificial vascular graft combined with antegrade stent grafting of the proximal descending aorta, performed in a single stage under moderate hypothermia (approx. 28°C).

干预措施: One-Stop Hybrid Surgery (Procedure)

Active Comparator: Conventional Group (n=70)

Active Comparator

Patients were randomized to undergo conventional total arch replacement using an integrated frozen elephant trunk (FET) hybrid prosthesis. The procedure was performed under deep hypothermic circulatory arrest (target temperature 23°C-25°C).

干预措施: Conventional Total Arch Replacement with Frozen Elephant Trunk (Procedure)

结局指标

主要结局

Incidence of the Composite Endpoint of 30-day Mortality, Stroke, and Acute Kidney Injury (Stage 2 or 3)

时间窗: Within 30 days post-procedure

A composite outcome measure including all-cause mortality, any new focal neurological deficit lasting \>24 hours and confirmed by imaging (stroke), and acute kidney injury defined as Stage 2 or 3 by KDIGO criteria. The measure is the percentage of patients in each group who experience at least one of these events.

Incidence of the Composite Endpoint of 30-day Mortality, Stroke, and Acute Kidney Injury (Stage 2 or 3)

时间窗: Within 30 days post-procedure

A composite outcome measure including all-cause mortality, any new focal neurological deficit lasting \>24 hours and confirmed by imaging (stroke), and acute kidney injury defined as Stage 2 or 3 by KDIGO criteria. The measure is the percentage of patients in each group who experience at least one of these events.

次要结局

  • All-Cause Mortality at 30 Days(Within 30 days post-procedure)
  • Incidence of Postoperative Stroke(Within 30 days post-procedure)
  • Incidence of Stage ≥2 Acute Kidney Injury (AKI)(Within 30 days post-procedure)
  • Operative Metrics(Intraoperative)
  • Duration of Mechanical Ventilation(During the postoperative hospital stay (up to 30 days post-procedure))
  • Incidence of Other Major Postoperative Complications(During hospital stay (up to 30 days post-procedure))
  • Change in Aortic Morphology Score(1 Month Post-procedure, 3 Months Post-procedure)
  • Change in Quality of Life(3 Months Post-procedure)
  • Incidence of Endoleak(1 Month Post-procedure, 3 Months Post-procedure)
  • Incidence of Cardiovascular Events(Through study completion (3 months))
  • Length of Intensive Care Unit (ICU) Stay(During the postoperative hospital stay (up to 30 days post-procedure))
  • Total Postoperative Hospital Stay(During the postoperative hospital stay (up to 30 days post-procedure))
  • All-Cause Mortality at 30 Days(Within 30 days post-procedure)
  • Incidence of Postoperative Stroke(Within 30 days post-procedure)
  • Incidence of Stage ≥2 Acute Kidney Injury (AKI)(Within 30 days post-procedure)
  • Operative Metrics(Intraoperative)
  • Duration of Mechanical Ventilation(During the postoperative hospital stay (up to 30 days post-procedure))
  • Incidence of Other Major Postoperative Complications(During hospital stay (up to 30 days post-procedure))
  • Change in Aortic Morphology Score(1 Month Post-procedure, 3 Months Post-procedure)
  • Change in Quality of Life(3 Months Post-procedure)
  • Incidence of Endoleak(1 Month Post-procedure, 3 Months Post-procedure)
  • Incidence of Cardiovascular Events(Through study completion (3 months))
  • Length of Intensive Care Unit (ICU) Stay(During the postoperative hospital stay (up to 30 days post-procedure))
  • Total Postoperative Hospital Stay(During the postoperative hospital stay (up to 30 days post-procedure))

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Qi Hu

Principal investigator

The First Hospital of Hebei Medical University

研究点 (2)

Loading locations...

相似试验